Clinical Trials Logo

Arthritis, Rheumatoid clinical trials

View clinical trials related to Arthritis, Rheumatoid.

Filter by:

NCT ID: NCT04999683 Completed - Clinical trials for Rheumatoid Arthritis

Effect of Anti-inflammatory (ITIS) Diet in Rheumatoid Arthritis

Start date: September 1, 2018
Phase: N/A
Study type: Interventional

to study the effect of anti-inflammatory diet on clinical and biological outcomes in rheumatoid arthritis

NCT ID: NCT04991753 Completed - Clinical trials for Arthritis, Rheumatoid

A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis

Start date: October 14, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of nipocalimab versus placebo in participants with moderate to severe active rheumatoid arthritis (RA).

NCT ID: NCT04985812 Completed - Clinical trials for Rheumatoid Arthritis

A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis

Start date: October 18, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety and tolerability of JNJ-67484703 administrations in participants with active rheumatoid arthritis (RA).

NCT ID: NCT04948775 Completed - Clinical trials for Rheumatoid Arthritis

Cervical Stabilization Exercises in Patients With Rheumatoid Arthritis

Start date: November 28, 2020
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the effectiveness of cervical stabilization exercises on cervical positioning error in rheumatoid arthritis.

NCT ID: NCT04933097 Completed - Clinical trials for Rheumatoid Arthritis

Evaluation of a New Screening Method for Sarcopenia in Rheumatoid Arthritis

SARCO-RA
Start date: July 29, 2021
Phase: N/A
Study type: Interventional

Evaluation of a new screening method for sarcopenia in rheumatoid arthritis

NCT ID: NCT04928066 Completed - Clinical trials for Arthritis, Rheumatoid

The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA

Start date: March 1, 2020
Phase: Phase 4
Study type: Interventional

RA is a common autoimmune disease that causes joint damage.It is necessary to reach the standard as soon as possible and give effective drugs according to the patient's disease activity to avoid disability. Tofacitinib(TF) is a new type of oral tyrosine kinase inhibitor (JAKi) for the treatment of moderate to severe active RA. However, there is alack of Chinese data on the joint scheme, long-term use, maintenance and stop of TF in the real world. We will use the new JAK combination regimen to treat RA patients, and carry out long-term clinical follow-up for 30 weeks.

NCT ID: NCT04911127 Completed - Clinical trials for Rheumatoid Arthritis

Therapeutic Response of Cannabidiol in Rheumatoid Arthritis

Start date: October 5, 2021
Phase: Phase 1
Study type: Interventional

The study will randomly assign Rheumatoid Arthritis (RA) patients on stable RA therapy to either placebo or cannabidiol (CBD). The overall goal of this proposal is to examine the efficacy and safety of CBD treatment as adjunctive to the medical management of RA patients.

NCT ID: NCT04880720 Completed - Clinical trials for Rheumatoid Arthritis

Deciphering a Specific Signature of the Immunosenescence Induced in COVID-19+ Patients Versus Rheumatoid Arthritis Patients

SENO-COVID
Start date: July 19, 2021
Phase:
Study type: Observational

Immune aging or immunosenescence is characterized by a loss of T cell clonal diversity and a contraction of naïve T cells with proliferative capacity associated with the functional impairment of many others immune cells as well as a chronic low degree of inflammation. A restrictive T cell repertoire is likely more prone to antigen-mediated exhaustion observed during chronic viral infections. Notably, lymphopenia is the most consistent laboratory abnormality in COVID-19 infected patients and both lung-resident and circulating T cells potently up-regulate markers of T cell exhaustion. It is not clear today if the association of COVID-19 disease severity with age is mainly related with the immunosenescence of infected patients. Interestingly, T cell exhaustion and premature immunosenescence have also been observed in chronic inflammatory diseases such as rheumatoid arthritis (RA). To better understand the immunological mechanisms involved in SARS-Cov-2 pathophysiology, the investigators propose to compare the immunosenescence patterns observed during RA, aging and SARS-Cov-2 infected patients in order to design improved therapeutic interventions.

NCT ID: NCT04850183 Completed - Clinical trials for Rheumatoid Arthritis

Effect of Education in Rheumatoid Arthritis

Start date: March 4, 2019
Phase: N/A
Study type: Interventional

This randomized controlled study aimed to determine the effect of education on disease management on the quality of life, and anxiety and depression levels of women with Rheumatoid Arthritis. The hypotheses of the current study are as below: H0: Education on disease management in women with Rheumatoid Arthritis does not affect the quality of life and anxiety and depression levels. H1: Education on disease management in women with Rheumatoid Arthritis affects the quality of life and anxiety and depression levels. Patients and Methods: The study was conducted with 66 women with Rheumatoid Arthritis (32 intervention, 34 control groups) at the rheumatology clinic and polyclinic of a university hospital between February and October 2019, in the city of Edirne, Turkey. Data were collected with "Patient Information Form", "Rheumatoid Arthritis Quality of Life Scale", "Health Assessment Questionnaire" and "Hospital Anxiety Depression Scale".

NCT ID: NCT04834557 Completed - Clinical trials for Rheumatoid Arthritis

Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis

Start date: November 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the potential therapeutic effects of the cardiac glycoside digoxin and the secondary bile acid ursodeoxycholic acid (UDCA) on synovial inflammation and disease activity when administered as add-on treatments to the current DMARDs treatments for rheumatoid arthritis patients with variant disease activity.